Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Richard M. Stone, M.D.

Co-Author

This page shows the publications co-authored by Richard Stone and Donald Kufe.
Connection Strength

2.222
  1. Tagde A, Rajabi H, Stroopinsky D, Gali R, Alam M, Bouillez A, Kharbanda S, Stone R, Avigan D, Kufe D. MUC1-C induces DNA methyltransferase 1 and represses tumor suppressor genes in acute myeloid leukemia. Oncotarget. 2016 Jun 28; 7(26):38974-38987.
    View in: PubMed
    Score: 0.185
  2. Stone RM, Bernstein SH, Demetri G, Facklam DP, Arthur K, Andersen J, Aster JC, Kufe D. Therapy with recombinant human erythropoietin in patients with myelodysplastic syndromes. Leuk Res. 1994 Oct; 18(10):769-76.
    View in: PubMed
    Score: 0.164
  3. Liu S, Yin L, Stroopinsky D, Rajabi H, Puissant A, Stegmaier K, Avigan D, Kharbanda S, Kufe D, Stone R. MUC1-C oncoprotein promotes FLT3 receptor activation in acute myeloid leukemia cells. Blood. 2014 Jan 30; 123(5):734-42.
    View in: PubMed
    Score: 0.155
  4. Stone RM, Spriggs DR, Arthur KA, Mayer RJ, Griffin J, Kufe DW. Recombinant human gamma interferon administered by continuous intravenous infusion in acute myelogenous leukemia and myelodysplastic syndromes. Am J Clin Oncol. 1993 Apr; 16(2):159-63.
    View in: PubMed
    Score: 0.148
  5. Yin L, Wu Z, Avigan D, Rosenblatt J, Stone R, Kharbanda S, Kufe D. MUC1-C oncoprotein suppresses reactive oxygen species-induced terminal differentiation of acute myelogenous leukemia cells. Blood. 2011 May 05; 117(18):4863-70.
    View in: PubMed
    Score: 0.129
  6. Stone RM, Spriggs DR, Dhawan RK, Arthur KA, Mayer RJ, Kufe DW. A phase I study of intermittent continuous infusion high dose cytosine arabinoside for acute leukemia. Leukemia. 1990 Dec; 4(12):843-7.
    View in: PubMed
    Score: 0.126
  7. Stone RM, Imamura K, Datta R, Sherman ML, Kufe DW. Inhibition of phorbol ester-induced monocytic differentiation and c-fms gene expression by dexamethasone: potential involvement of arachidonic acid metabolites. Blood. 1990 Sep 15; 76(6):1225-32.
    View in: PubMed
    Score: 0.124
  8. Yin L, Ahmad R, Kosugi M, Kawano T, Avigan D, Stone R, Kharbanda S, Kufe D. Terminal differentiation of chronic myelogenous leukemia cells is induced by targeting of the MUC1-C oncoprotein. . 2010 Sep 01; 10(5):483-91.
    View in: PubMed
    Score: 0.124
  9. Ahmad R, Liu S, Weisberg E, Nelson E, Galinsky I, Meyer C, Kufe D, Kharbanda S, Stone R. Combining the FLT3 inhibitor PKC412 and the triterpenoid CDDO-Me synergistically induces apoptosis in acute myeloid leukemia with the internal tandem duplication mutation. Mol Cancer Res. 2010 Jul; 8(7):986-93.
    View in: PubMed
    Score: 0.122
  10. Stone RM, Weber BL, Spriggs DR, Kufe DW. Phospholipase C activates protein kinase C and induces monocytic differentiation of HL-60 cells. Blood. 1988 Aug; 72(2):739-44.
    View in: PubMed
    Score: 0.107
  11. Stone RM, Sariban E, Pettit GR, Kufe DW. Bryostatin 1 activates protein kinase C and induces monocytic differentiation of HL-60 cells. Blood. 1988 Jul; 72(1):208-13.
    View in: PubMed
    Score: 0.107
  12. Kawano T, Ito M, Raina D, Wu Z, Rosenblatt J, Avigan D, Stone R, Kufe D. MUC1 oncoprotein regulates Bcr-Abl stability and pathogenesis in chronic myelogenous leukemia cells. Cancer Res. 2007 Dec 15; 67(24):11576-84.
    View in: PubMed
    Score: 0.103
  13. Gong J, Koido S, Kato Y, Tanaka Y, Chen D, Jonas A, Galinsky I, DeAngelo D, Avigan D, Kufe D, Stone R. Induction of anti-leukemic cytotoxic T lymphocytes by fusion of patient-derived dendritic cells with autologous myeloblasts. Leuk Res. 2004 Dec; 28(12):1303-12.
    View in: PubMed
    Score: 0.083
  14. Kaneki M, Kharbanda S, Pandey P, Yoshida K, Takekawa M, Liou JR, Stone R, Kufe D. Functional role for protein kinase Cbeta as a regulator of stress-activated protein kinase activation and monocytic differentiation of myeloid leukemia cells. Mol Cell Biol. 1999 Jan; 19(1):461-70.
    View in: PubMed
    Score: 0.055
  15. Eder JP, Rubin E, Stone R, Bryant M, Xu G, Supko J, Kinchla N, Lynch T, Hurwitz S, Rodriguez D, Shapiro C, Toppmeyer D, Grossbard M, Vosburg E, Huberman M, Schnipper L, Shulman L, Kufe DW. Trials of 9-amino-20(S)-camptothecin in Boston. Ann N Y Acad Sci. 1996 Dec 13; 803:247-55.
    View in: PubMed
    Score: 0.048
  16. Rosenblatt J, Stone RM, Uhl L, Neuberg D, Joyce R, Levine JD, Arnason J, McMasters M, Luptakova K, Jain S, Zwicker JI, Hamdan A, Boussiotis V, Steensma DP, DeAngelo DJ, Galinsky I, Dutt PS, Logan E, Bryant MP, Stroopinsky D, Werner L, Palmer K, Coll M, Washington A, Cole L, Kufe D, Avigan D. Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions. Sci Transl Med. 2016 12 07; 8(368):368ra171.
    View in: PubMed
    Score: 0.048
  17. Yang KD, Mizobuchi T, Kharbanda SM, Datta R, Huberman E, Kufe DW, Stone RM. All-trans retinoic acid reverses phorbol ester resistance in a human myeloid leukemia cell line. Blood. 1994 Jan 15; 83(2):490-6.
    View in: PubMed
    Score: 0.039
  18. Kharbanda S, Saleem A, Emoto Y, Stone R, Rapp U, Kufe D. Activation of Raf-1 and mitogen-activated protein kinases during monocytic differentiation of human myeloid leukemia cells. J Biol Chem. 1994 Jan 14; 269(2):872-8.
    View in: PubMed
    Score: 0.039
  19. Stroopinsky D, Rosenblatt J, Ito K, Mills H, Yin L, Rajabi H, Vasir B, Kufe T, Luptakova K, Arnason J, Nardella C, Levine JD, Joyce RM, Galinsky I, Reiter Y, Stone RM, Pandolfi PP, Kufe D, Avigan D. MUC1 is a potential target for the treatment of acute myeloid leukemia stem cells. Cancer Res. 2013 Sep 01; 73(17):5569-79.
    View in: PubMed
    Score: 0.038
  20. Bernstein SH, Kharbanda SM, Sherman ML, Stone RM, Kufe DW. Inhibition of protein kinase C is associated with a decrease in c-myc expression in human myeloid leukemia cells. FEBS Lett. 1991 Dec 02; 294(1-2):73-6.
    View in: PubMed
    Score: 0.034
  21. Kharbanda S, Nakamura T, Stone R, Hass R, Bernstein S, Datta R, Sukhatme VP, Kufe D. Expression of the early growth response 1 and 2 zinc finger genes during induction of monocytic differentiation. J Clin Invest. 1991 Aug; 88(2):571-7.
    View in: PubMed
    Score: 0.033
  22. Datta R, Sherman ML, Stone RM, Kufe D. Expression of the jun-B gene during induction of monocytic differentiation. Cell Growth Differ. 1991 Jan; 2(1):43-9.
    View in: PubMed
    Score: 0.032
  23. Brach M, Stone R, Kufe D. CSFs in combination with cytosine arabinoside, an inhibitor of DNA synthesis: potential strategies for the treatment of myeloid disorders. Biotechnol Ther. 1991; 2(3-4):269-83.
    View in: PubMed
    Score: 0.032
  24. Sherman ML, Stone RM, Datta R, Bernstein SH, Kufe DW. Transcriptional and post-transcriptional regulation of c-jun expression during monocytic differentiation of human myeloid leukemic cells. J Biol Chem. 1990 Feb 25; 265(6):3320-3.
    View in: PubMed
    Score: 0.030
  25. Rosenblatt J, Wu Z, Vasir B, Zarwan C, Stone R, Mills H, Friedman T, Konstantinopoulos PA, Spentzos D, Ghebremichael M, Stevenson K, Neuberg D, Levine JD, Joyce R, Tzachanis D, Boussiotis V, Kufe D, Avigan D. Generation of tumor-specific T lymphocytes using dendritic cell/tumor fusions and anti-CD3/CD28. J Immunother. 2010 Feb-Mar; 33(2):155-66.
    View in: PubMed
    Score: 0.030
  26. Horiguchi J, Spriggs D, Imamura K, Stone R, Luebbers R, Kufe D. Role of arachidonic acid metabolism in transcriptional induction of tumor necrosis factor gene expression by phorbol ester. Mol Cell Biol. 1989 Jan; 9(1):252-8.
    View in: PubMed
    Score: 0.028
  27. Wakamiya N, Stone R, Takeyama H, Spriggs D, Kufe D. Detection of tumor necrosis factor gene expression at a cellular level in human acute myeloid leukemias. Leukemia. 1989 Jan; 3(1):51-6.
    View in: PubMed
    Score: 0.028
  28. Spriggs DR, Stone RM, Kufe DW. The treatment of myelodysplastic syndromes. Clin Haematol. 1986 Nov; 15(4):1081-107.
    View in: PubMed
    Score: 0.024
  29. Andreeff M, Stone R, Michaeli J, Young CW, Tong WP, Sogoloff H, Ervin T, Kufe D, Rifkind RA, Marks PA. Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent. Blood. 1992 Nov 15; 80(10):2604-9.
    View in: PubMed
    Score: 0.009
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.